| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
|
Medicine details |
|
| Medicine name | secukinumab (Cosentyx®) |
| Formulation | 150 mg/ 1ml solution for injection |
| Reference number | 1307 |
| Indication | Treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 18/02/2016 |
| NICE guidance | |